Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 678-686

  Hurtado, Felipe K ^a   Weber, Benjamin ^b   Derendorf, Hartmut ^b   Hochhaus, Guenther ^b   Costa, Teresa Dalla ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALIBRATION; COMPARTMENT MODEL; CONTROLLED STUDY; DIFFUSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; IN VITRO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROSTATE; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; LEVOFLOXACIN; MALE; MICRODIALYSIS; PERMEABILITY; PROSTATE; PROTEIN BINDING; RATS; RATS, WISTAR;

EID: 84893472261     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01884-13     Document Type: Article

References (37)

1. Wagenlehner FME, Naber KG. 2005. Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. Curr. Infect. Dis. Rep. 7:9-16. http://dx.doi.org/10.1007/s11908-005-0018-9.
2. Naber KG, Weidner W. 2000. Chronic prostatitis-an infectious disease? J. Antimicrob. Chemother. 46:157-161. http://dx.doi.org/10.1093/jac/46.2.157.
3. Naber KG, Sorgel F. 2003. Antibiotic therapy-rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 35:331-335. http://dx.doi.org/10.1046/j.1439-0272.2003.00568. x.
4. Naber KG. 2008. Management of bacterial prostatitis: what's new? BJU Int. 101:7-10. http://dx.doi.org/10.1111/j.1464-410X.2008.07495.x.
5. Naber CK, Steghafner M, Kinzig-Schippers M, Sauber C, Sorgel F, Stahlberg HJ, Naber KG. 2001. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob. Agents Chemother. 45:293-297. http://dx.doi.org/10.1128/AAC.45.1.293-297.2001.
6. Wagenlehner FME, Kees F, Weidner W, Wagenlehner C, Naber KG. 2008. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int. J. Antimicrob. Agents 31:21-26. http://dx.doi.org/10. 1016/j.ijantimicag.2007.08.025.
7. Drusano GL, Preston SL, Van Guilder M, North D, Gombert M, Oefelein M, Boccumini L, Weisinger B, Corrado M, Kahn J. 2000. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob. Agents Chemother. 44:2046-2051. http://dx.doi.org/10.1128/AAC.44.8.2046-2051.2000.
8. Croom KF, Goa KL. 2003. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63:2769-2802. http://dx.doi.org/10.2165/00003495-200363240-00008.
9. Bulitta JB, Kinzig M, Naber CK, Wagenlehner FME, Sauber C, Landersdorfer CB, Soergel F, Naber KG. 2011. Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination. Chemotherapy 57:402-416. http://dx.doi.org/10.1159/000329520.
10. Van Bambeke F, Tulkens PM. 2009. Safety profile of the respiratory fluoroquinolone moxifloxacin comparison with other fluoroquinolones and other antibacterial classes. Drug Safety 32:359-378. http://dx.doi.org/10.2165/ 00002018-200932050-00001.
11. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237. http://dx.doi.org/10.1093/jac/dkm476.
12. Muller M, Stass H, Brunner M, Moller JG, Lackner E, Eichler HG. 1999. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob. Agents Chemother. 43:2345-2349.
13. Joukhadar C, Derendorf H, Muller M. 2001. Microdialysis: a novel tool for clinical studies of anti-infective agents. Eur. J. Clin. Pharmacol. 57: 211-219. http://dx.doi.org/10.1007/s002280100301.
14. Elmquist WF, Sawchuk RJ. 1997. Application of microdialysis in pharmacokinetic studies. Pharm. Res. 14:267-288. http://dx.doi.org/10.1023/A: 1012081501464.
15. Freddo RJ, Costa TD. 2002. Determination of norfloxacin free interstitial levels in skeletal muscle by microdialysis. J. Pharm. Sci. 91:2433-2440. http://dx.doi.org/10.1002/jps.10230.
16. de Araujo BV, Diniz A, Palma EC, Buffe C, Costa TD. 2011. PK-PD modeling of beta-lactam antibiotics: in vitro or in vivo models? J. Antibiot. 64:439-446. http://dx.doi.org/10.1038/ja.2011.29.
17. Tasso L, Bettoni C, Oliveira L, Costa T. 2008. Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats. Int. J. Pharm. 358:96-101. http://dx.doi.org/10.1016/j.ijpharm.2008.02.023.
18. de Araujo BV, da Silva CF, Haas SE, Dalla Costa T. 2009. Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats. Int. J. Antimicrob. Agents 33:154-159. http://dx.doi.org/10.1016/j.ijantimicag.2008.08.020.
19. Azeredo F, Araujo B, Haas S, Torres B, Pigatto M, Andrade C, Dalla Costa T. 2012. Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats. Antimicrob. Agents Chemother. 56:5852-5857. http://dx.doi.org/10.1128/AAC.01323-12.
20. de Lange ECM, de Boer AG, Breimer DD. 2000. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv. Drug Deliv. Rev. 45:125-148. http://dx.doi.org/10.1016/S0169-409X(00)00107-1.
21. Whitaker G, Lunte CE. 2010. Investigation of microdialysis sampling calibration approaches for lipophilic analytes: doxorubicin. J. Pharm. Biomed. Anal. 53:490-496. http://dx.doi.org/10.1016/j.jpba.2010.05.023.
22. Shargel L, Wu-Pong S, Yu ABC. 2005. Applied biopharmaceutics and pharmacokinetics, 5th ed. McGraw-Hill Book Co, New York, NY.
23. Plock N, Kloft C. 2005. Microdialysis: theoretical background and recent implementation in applied life-sciences. Eur. J. Pharm. Sci. 25:1-24. http://dx.doi.org/10.1016/j.ejps.2005.01.017.
24. Konety BR, Somogyi G, Atan A, Muindi J, Chancellor MB, Getzenberg RH. 2002. Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitaminD3 (calcitriol) using a microdialysis technique. Urology 59:947-952. http://dx.doi.org/10.1016/S0090-4295(01)01652-1.
25. Bansal S, DeStefano A. 2007. Key elements of bioanalytical method validation for small molecules. AAPS J. 9:E109-E114. http://dx.doi.org/10.1208/ aapsj0901011.
26. Food and Drug Administration. 2001. Guidance for industry: bioanalytical method validation. U.S. Food and Drug Administration, Washington, DC.
27. Hutschala D, Skhirtladze K, Zuckermann A, Wisser W, Jaksch P, Mayer-Helm B, Burgmann H, Wolner E, Muller M, Tschernko E. 2005. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob. Agents Chemother. 49:5107-5111. http://dx.doi.org/10.1128/AAC.49.12.5107-5111. 2005.
28. Zeitlinger MA, Traunmueller F, Abrahim A, Mueller MR, Erdogan Z, Mueller M, Joukhadar C. 2007. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. Int. J. Antimicrob. Agents 29:44-50. http://dx.doi.org/10.1016/j.ijantimicag.2006.08.045.
29. Marchand S, Frasca D, Dahyot-Fizelier C, Breheret C, Mimoz O, Couet W. 2008. Lung microdialysis study of levofloxacin in rats following intravenous infusion at steady state. Antimicrob. Agents Chemother. 52:3074-3077. http://dx.doi.org/10.1128/AAC.00242-08.
30. Perletti G, Wagenlehner F, Naber K, Magrid V. 2009. Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue. Int. J. Antimicrob. Agents 33:206-210. http://dx.doi.org/10.1016/j.ijantimicag.2008.09.009.
31. Ito T, Yano I, Masuda S, Hashimoto Y, Inui K. 1999. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. Pharm. Res. 16:534-539. http://dx.doi.org/10.1023/A:1018871029244.
32. Kruh GD, Belinsky MG. 2003. The MRP family of drug efflux pumps. Oncogene 22:7537-7552. http://dx.doi.org/10.1038/sj.onc.1206953.
33. Tamai I, Yamashita J, Kido Y, Ohnari A, Sai Y, Shima Y, Naruhashi K, Koizumi S, Tsuji A. 2000. Limited distribution of new quinolone antibacterial agents into brain causedbymultiple efflux transporters at the blood-brain barrier. J. Pharm. Exp. Ther. 295:146-152.
34. Nobili S, Landini I, Mazzei T, Mini E. 2012. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med. Res. Rev. 32:1220-1262. http://dx.doi.org/10.1002/med.20239.
35. Mueller M, de la Pena A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48:369-377. http://dx.doi.org/10.1128/AAC.48.2. 369-377.2004.
36. Nickel JC, Downey J, Clark J, Ceri H, Olson M. 1995. Antibiotic pharmacokinetics in the inflamed prostate. J. Urol. 153:527-529. http://dx.doi.org/10.1097/00005392-199502000-00076.
37. European Committee on Antimicrobial Susceptibility Testing. 2013. Breakpoint tables for interpretation of MICs and zone diameters, version 3.1. European Committee on Antimicrobial Susceptibility Testing, Basel, Switzerland.